| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Fingolimod HCl (formerly FTY-720; FTY 720; Gilenia and Gilenya), an FDA approved drug for the treatment of Multiple sclerosis, is a S1P (sphingosine 1-phosphate) antagonist with potential antineoplastic activity. It reduces S1P in K562 and NK cells with an IC50 of 0.033 nM. Fungi is the source of this traditional remedy. In organ transplantation, fungolimod was initially discovered to be a therapeutic agent. Receptor-mediated effects on the immune system and central nervous system (CNS) are how it contributes to MS treatment. With its antineoplastic properties, fingolimod is used to treat multiple sclerosis.
| Targets |
S1P ( IC50 = 0.033 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
Immature DCs are either left unaltered or incubated for four hours with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871, or S1P combined with these medications. LPS at 1 μg/mL is used as a control. After being cleaned and placed in a 96-well plate with a v-bottom and 2 × 105 cells per well, the cells are once more washed and reconstituted in PBS buffer that contains 0.1% sodium azide. One microgram per milliliter of FITC-conjugated mouse anti-human CD80, one microgram per milliliter of FITC-conjugated mouse anti-human CD83, one microgram per milliliter of FITC-conjugated mouse anti-human CD86, one microgram per milliliter of FITC-conjugated mouse anti-human HLA-class I, one microgram per milliliter of FITC-conjugated mouse anti-human HLA-DR, one microgram per milliliter of FITC-conjugated mouse anti-human HLA-E, or one microgram per milliliter of FITC-conjugated mouse IgG are used as labels for them. After two rounds of washing, the cells are examined in a flow cytometer. Markers are set using FITC-conjugated mouse IgG as the isotype control. NK cells are either left untreated or incubated with 2 μM S1P for 4 hours, after which they are washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 minutes at 4 °C. To further stain NK cells, 1 μg/mL of FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody is used. This antibody recognizes KIR2DL2, KIR2DL3, KIR2DS2, and KIR2DS4, and FITC-conjugated mouse IgG is used as a control. After two rounds of washing, the cells are examined in a flow cytometer. Markers are set in accordance with the isotype control mouse IgG that is conjugated with either PE or FITC.
|
|
| Animal Protocol |
|
|
| References |
| Molecular Formula |
C19H34CLNO2
|
|---|---|
| Molecular Weight |
343.9
|
| Exact Mass |
343.23
|
| Elemental Analysis |
C, 66.35; H, 9.96; Cl, 10.31; N, 4.07; O, 9.30
|
| CAS # |
162359-56-0
|
| Related CAS # |
Fingolimod; 162359-55-9
|
| Appearance |
Solid powder
|
| SMILES |
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
|
| InChi Key |
SWZTYAVBMYWFGS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
|
| Chemical Name |
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
|
| Synonyms |
FTY720; Fingolimod HCl; FTY-720; FTY 720; Trade name: Gilenia and Gilenya.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9078 mL | 14.5391 mL | 29.0782 mL | |
| 5 mM | 0.5816 mL | 2.9078 mL | 5.8156 mL | |
| 10 mM | 0.2908 mL | 1.4539 mL | 2.9078 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04667949 | Active Recruiting |
Drug: Fingolimod 0.5mg | Relapsing Multiple Sclerosis (RMS) |
Novartis Pharmaceuticals | February 20, 2021 | Phase 4 |
| NCT04088630 | Active Recruiting |
Drug: Fingolimod 0.5 mg Drug: Placebo |
Cerebral Edema Stroke Hemorrhagic |
Wake Forest University Health Sciences |
August 7, 2020 | Early Phase 1 |
| NCT05423769 | Active Recruiting |
Drug: Fingolimod | Relapsing-Remitting Multiple Sclerosis |
Hikma Pharmaceuticals LLC | January 19, 2022 | N/A |
| NCT04480853 | Recruiting | Drug: Fingolimod | Multiple Sclerosis | Novartis Pharmaceuticals | October 12, 2020 | Phase 4 |
| NCT01285479 | Completed | Drug: Fingolimod | Multiple Sclerosis | Novartis Pharmaceuticals | October 15, 2011 | N/A |
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
